AZD1390 ATM Kinase Inhibitor Workflow
2026-09-14
Build mechanism-focused radiation and DNA damage response assays with AZD1390, an ATM kinase inhibitor suited to glioma and lung cancer models. The workflow connects checkpoint disruption with replication-fork stress, G-quadruplex biology, and practical assay troubleshooting.
Deep Learning for iPSC-CM Cardiotoxicity Screening
2026-09-14
Grafton et al. developed a scalable phenotypic screening strategy that combines high-content imaging, induced pluripotent stem cell-derived cardiomyocytes, and deep learning to identify cardiotoxic patterns. The study shows how a single computational score can prioritize liabilities across known and previously uncharacterized compounds while supporting earlier safety decisions.
EZ Cap™ Mouse IL-12 mRNA (m1Ψ) Workflow
2026-09-13
Build reproducible IL-12 expression assays by combining Cap 1, m1Ψ-modified mRNA with controlled delivery, immune phenotyping, and tissue-aware experimental design. The workflow also shows how recent virus-mimicking particles can extend cytokine mRNA studies beyond conventional liver-biased delivery.
Ferrostatin-1 (Fer-1) in Glioma Death-Mapping
2026-09-12
Ferrostatin-1 (Fer-1) can do more than rescue ferroptotic cells: it can help distinguish lipid-peroxidation-driven death from cuproptosis in glioma models. This guide translates copper-homeostasis findings into a rigorous, pathway-resolved ferroptosis assay strategy.
ARL4C, FLSs, and Macrophage Dynamics in RA
2026-09-11
The reference study integrates single-cell and bulk transcriptomics with functional perturbation, coculture, and collagen-induced arthritis experiments to identify ARL4C as a regulator of aggressive fibroblast-like synoviocytes in rheumatoid arthritis. Its findings connect ARL4C-dependent synoviocyte proliferation and invasion with macrophage polarization, while local ARL4C silencing reduces joint pathology in rats.
Targeted mRNA Nanoparticles Repair the Poststroke BBB
2026-09-11
Gao and colleagues developed mannose-targeted lipid nanoparticles that deliver interleukin-10 mRNA to microglia in ischemic brain regions. In mouse stroke models, this strategy promoted protective microglial polarization, reduced neuroinflammation, restored blood–brain barrier integrity, and improved neurological outcomes, while suggesting a potentially extended treatment window.
Surrogate BBB Model for CNS Permeability Screening
2026-09-10
Hu and colleagues developed a high-throughput LLC-PK1-MOCK/MDR1 Transwell model that links directional permeability measurements with unbound brain-to-plasma distribution. Its integration of P-glycoprotein activity and lysosomal trapping correction improves interpretation of screening data and supports earlier CNS candidate prioritization.
PD 173074 Workflows for FGFR1 Signaling Research
2026-09-10
PD 173074 enables concentration-matched interrogation of FGFR1 and VEGFR2 in kinase, cancer-cell, angiogenesis, and resistance models. Its strongest use is as a mechanistic probe paired with pathway biomarkers, genetic context, and carefully controlled exposure conditions.
KX2-391 as an HBV Transcription Inhibitor
2026-09-09
Harada and colleagues used a recombinant NanoLuc-reporting HBV system to identify KX2-391 as a small-molecule inhibitor of HBV transcription. Their experiments linked the antiviral phenotype to inhibition of tubulin polymerization rather than Src kinase suppression, providing a mechanistic basis for repurposing this scaffold in HBV research.
CSBTA Pharmacokinetics in MASH Mice
2026-09-09
The reference study integrates plasma pharmacokinetics, tissue distribution, cellular uptake, and enzyme–transporter analysis to explain how MASH alters exposure to Corydalis saxicola Bunting total alkaloids. Its findings show disease-state-dependent accumulation of dehydrocavidine, palmatine, and berberine, providing a mechanistic basis for exposure-aware dosing research in MASLD/MASH.
4-PBA: Turning ER Stress Into Causal Evidence
2026-09-08
4-Phenylbutyric acid is most valuable when used not simply to suppress stress markers, but to test whether proteostasis disruption causally drives autophagic cell death. This thought-leadership guide translates recent liver cancer evidence into a rigorous workflow for ER stress alleviation, pathway validation, and translational decision-making.
BRD4770: A G9a Inhibitor for Causal Epigenetics
2026-09-08
BRD4770 is a G9a histone methyltransferase inhibitor for linking H3K9 methylation changes to senescence and cancer-cell phenotypes. This article provides an assay-centered framework for interpreting BRD4770 data across PANC-1 models and the c-MYC–G9a axis described in breast cancer research.
Omeprazole A2845: Research Protocol Guidance
2026-09-07
Omeprazole (A2845) is a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research and antiulcer activity studies. This guidance covers solvent selection, assay setup, storage, and quality control; the material is for scientific research only and should not be used for diagnostic, therapeutic, or medical applications.
4-Ethylphenyl Sulfate: Applied Research Workflows
2026-09-07
4-Ethylphenyl sulfate connects renal biomarker measurement, gut microbiota-brain interaction research, and controlled surface-adsorption experiments in one defined metabolite workflow. This guide provides practical handling, assay-design, and troubleshooting strategies for reproducible studies across renal dysfunction and autism spectrum disorder models.
Trelagliptin succinate: Adipocyte Assay Workflows
2026-09-05
Build more informative diabetes mellitus research workflows with Trelagliptin succinate, from DPP-4 activity testing to PI3K/AKT/GLUT4 analysis in insulin-resistant adipocytes. The guide connects assay design, formulation control, pathway readouts, and troubleshooting with evidence from a focused reference study.